This cohort study examines the association of treatment strategy and clinicopathologic factors with progression-free and overall survival in patients with hormone receptor–positive, ERBB2-negative breast cancer with metastasis after treatment with endocrine and cyclin-dependent kinase 4/6 inhibitor therapy. This evidence concerns the gene ERBB2 and breast carcinoma.